

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhongzhi Pharmaceutical Holdings Limited
中智藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3737)

SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2017

Reference is made to the annual report (the “**Annual Report**”) of Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”) for the year ended 31 December 2017. Unless otherwise stated, capitalized terms used herein shall have the same meanings as defined in the Annual Report.

In addition to the information in relation to the subscribing of 40,000,000 ordinary Shares at a subscription price of HK\$1.53 per Share on 27 October 2017 as set out in the Annual Report, the board (the “**Board**”) of the directors (the “**Directors**”) of the Company would like to provide additional information in relation to the use of net proceeds raised from the Subscription.

The net proceeds raised from the Subscription were approximately HK\$60,800,000, out of which approximately HK\$27,785,000 has been utilized for distribution network of the Company. As at 31 December 2017, the unutilized amount of approximately HK\$33,015,000 is intended to be used for distribution network of the Company by the end of February 2018.

As at 30 June 2018, all the net proceeds raised from the Subscription has been fully unutilized.

The above additional information does not affect other information contained in the Annual Report and, save as disclosed in this announcement, the remaining contents of the Annual Report remain unchanged.

By order of the Board
Zhongzhi Pharmaceutical Holdings Limited
Mr. Lai Zhi Tian
Chairman and Executive Director

Hong Kong, 24 July 2018

As at the date of this announcement, the Board comprises nine Directors. The executive Directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Cao Xiao Jun and Mr. Cheng Jin Le. The non-executive Directors are Ms. Jiang Li Xia and Mr. Yang Ai Xing. The independent non-executive Directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.